Désiré Collen holds a M.D. degree (1968) and Ph.D. degree in Chemistry (1974) from Katholieke Universiteit Leuven, Belgium. He served as Director of the Molecular Cardiovascular Medicine Group (comprising the Center for Molecular and Vascular Biology of the Katholieke Universiteit Leuven, and the Vesalius Research Center of the Flanders Institute for Biotechnology) in Leuven, Belgium until September 2008. He has research interests in translational research in biopharmaceutical drug development. His team initially developed t-PA, still the most effective drug for thrombolytic therapy of acute myocardial infarction. Dr. Collen has co-authored over 650 research papers and has received four honorary doctorates and several scientific awards including the Francqui Prize (Belgium), the Prix Louis Jeantet de Médecine (Switzerland), the Bristol-Myers-Squibb award for Cardiovascular Research (USA), and the Health Prize of the Interbrew-Baillet Latour Fund (Belgium) (jointly with P. Carmeliet). He was the Founder of and until August 2008 Chief Executive Officer of ThromboGenics, NV, a biopharmaceutical drug development company listed on Euronext Brussels. Till beginning of December 2013 he was the Chairman of the Board of ThromboGenics NV.
Raymond De Bondt is professor emeritus of Managerial Economics, Strategy and Innovation at the Katholieke Universiteit Leuven. He holds a Ph.D. in Managerial Economics from Northwestern University (1974). He has been president of the European Association for Research in Industrial Economics (1993-1995), dean of the Faculty of Economic and Applied Economic Sciences of the K.U.Leuven (1994-1997), chairperson of Leuven Research and Development (1995-2005), chief editor of the International Journal of Industrial Organisation (1993-1996), and of the “Tijdschrift voor Economie en Management” (1982-1991). He serves currently as executive director of the Innovation and Incubation centre of the K.U. Leuven at the Arenberg campus in Heverlee (since 2008). De Bondt has been visiting professor of managerial economics at the Kellogg School of Management of the Northwestern University in the USA and Israel, the School of Management of the University of California in Los Angeles, the Vlerick Leuven Gent Management School in Leuven, Belgium, the School of Business, Sun Yat-Sen University in Guangzhou, China, the National Institute for Public Administration in Kuala-Lumpur, Malaysia, and Lovanium-Leti in St Petersburg, Russia. His publications include contributions in the Canadian Journal of Economics, China Management Review, Econometrica, Economics of Innovation and New Technology, Economisch en Sociaal Tijdschrift, European Economic Review, European Journal of Political Economy, Journal of Economic Theory, Journal of Industry, Competition and Trade, Journal of Industrial Economics, International Journal of Industrial Organization, Maandschrift Economie, Review of Business and Economics, The Antitrust Bulletin and the Tijdschrift voor Economie en Management. His books include “ Innovatie en Multinationals “ (1988) (with L. Sleuwaegen), “Met vrije handen in markten en organisaties” (2000), “Elementen van Bedrijfseconomie” (2006) and “Theorie van de Industriële Organisatie” (2006)”.
Guy Mannaerts is emeritus professor at the faculty of medicine and chairman of the University of Leuven Hospitals, the National Multiple Sclerosis Centre, the Flemish Hospital Network of the Katholieke Universiteit Leuven and a number of University Hospital spin off companies.
He is board member of the Katholieke Universiteit Leuven and of several general hospitals, that have close links with the University Hospital.
He obtained MD and PhD degrees from the Katholieke Universiteit Leuven. After a postdoctoral fellowship at the University of Texas at Dallas, he was appointed professor of Pharmacology at the Leuven Medical Faculty. His research included lipid metabolism and peroxisome biochemistry and biogenesis.
He was, successively, dean of the faculty, vice-rector for the Biomedical Sciences, board member of the university and chairman of the hospital.
Until June 2014, Chris Buyse was CFO at ThromboGenics NV. He has 25 years of experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign, where he coordinated its acquisition by BASF in early 2007. Before this, Mr. Buyse was Finance Director of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecom companies, and was CFO and interim CEO of Keyware Technologies, reporting to the President of the Board. In addition, he held several financial positions as financial controller and internal auditor at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever.